179P - The results of neoadjuvant chemoradiation therapy in combined treatment of rectal cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Rectal Cancer
Surgical oncology
Presenter Abror Abdujapparov
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors A.S. Abdujapparov1, Y.V. Ten2, B.S. Korakhadjaev2
  • 1Oncology And Radiological Diagnostics, Tashkent Medical Academy, 100109 - Tashkent/UZ
  • 2Proctology, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ



The aim of this study was to improve long-term results of treatment of resectable rectal cancer stage I - II through the optimization scheme of neoadjuvant chemoradiation therapy.


The study of the efficacy of the developed neoadjuvant method of treatment of colorectal cancer with the use of remote large-fraction radiotherapy (LFRT) SD 5gr, cumulative dose 25gr conducted in patients receiving capecitabine at a dose of 1700 mg/m2 during the entire course of radiation therapy, local intracavitary microwave hyperthermia (MH) 3, 4 and 5 days, and a course of intrarectal administered metronidazole (MTZ) radiosensitizing mixture on days 3 and 5 of the course. Study group: 53 patients with resectable rectal cancer (LFRT + capecitabine + MH + MTZ). Control group: 54 patients with resectable rectal cancer who received the standard neoadjuvant large-fraction radiotherapy. After neoadjuvant treatment, all patients underwent radical resection within 5-7 days.


Evaluation of the composition of the study and control groups of patients showed their complete identity for the main prognostic features. In the study group, postoperative complications were seen in 5 (9.4%) cases; in the control group, which received LFRT postoperative complications were seen in 6 (11.1%) cases, respectively. The use of preoperative LFRT in patients receiving capecitabine, microwave hyperthermia and metronidazole has increased the 5-year survival rate to 69.8%, compared with the control group, receiving LFRT, where the 5-year survival rate was 61.5%. The incidence of local recurrence was 2.2%, and the frequency of distant metastases of 9.6% in the study group, and in the control group of local recurrence rate of 2.6%, and distant metastasis rate of 11.6%.


The neoadjuvant treatment method using (LFRT + capecitabine + MH + MTZ) in the combination therapy of resectable rectal cancer does not affect the intra and postoperative frequency of complications and increases the 5-year survival compared with that in patients who received standard neoadjuvant LFRT.

Clinical trial indentification

Legal entity responsible for the study

Navruzov S.N.




All authors have declared no conflicts of interest.